MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center

[1]  Kathryn J Fowler,et al.  Abbreviated Magnetic Resonance Imaging for HCC Surveillance , 2021, Clinical liver disease.

[2]  Kathryn J Fowler,et al.  Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening , 2020, European Radiology.

[3]  Weiyi Wang,et al.  Advances in the early diagnosis of hepatocellular carcinoma , 2020, Genes & diseases.

[4]  C. McCulloch,et al.  Racial and Ethnic Disparities in Kidney Transplant Access Within a Theoretical Context of Medical Eligibility , 2019, Transplantation.

[5]  M. O'Boyle,et al.  Role of US LI-RADS in the LI-RADS Algorithm. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.

[6]  C. Beauchemin,et al.  Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. , 2019, AJR. American journal of roentgenology.

[7]  N. Weiss,et al.  No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. , 2018, Gastroenterology.

[8]  Kathryn J Fowler,et al.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. , 2018, Radiology.

[9]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[10]  Jiaquan Xu.  Trends in Liver Cancer Mortality Among Adults Aged 25 and Over in the United States, 2000-2016. , 2018, NCHS data brief.

[11]  H. El‐Serag,et al.  Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis , 2018, Hepatology.

[12]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[13]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[14]  Qi Zhao,et al.  Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. , 2017, Nature materials.

[15]  J. Marrero,et al.  Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. , 2017, The American journal of medicine.

[16]  B. Taouli,et al.  Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis , 2017, Clinical and translational gastroenterology.

[17]  J. Byun,et al.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma , 2017, JAMA oncology.

[18]  Y. Hoshida,et al.  Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated? , 2017, Current Hepatology Reports.

[19]  J. Marrero,et al.  Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis , 2017, Alimentary pharmacology & therapeutics.

[20]  H. El‐Serag,et al.  Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. , 2016, Journal of hepatology.

[21]  Ahmedin Jemal,et al.  Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.

[22]  K. McGlynn,et al.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.

[23]  M. O'Boyle,et al.  2077859 Ultrasound In HCC Surveillance: What Is The Quality Of Ultrasound And What Factors Affect Quality? , 2015 .

[24]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, JNCI Journal of the National Cancer Institute.

[25]  Robert M. Marks,et al.  Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. , 2015, AJR. American journal of roentgenology.

[26]  Mark R Schultz,et al.  False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. , 2014, Journal of clinical epidemiology.

[27]  Y. Kono,et al.  Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA , 2014, Digestive Diseases and Sciences.

[28]  K. Flegal,et al.  Prevalence of childhood and adult obesity in the United States, 2011-2012. , 2014, JAMA.

[29]  P. Thuras,et al.  Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study , 2013, Alimentary pharmacology & therapeutics.

[30]  J. Marrero,et al.  Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[31]  William M. Lee,et al.  Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review , 2012, Journal of General Internal Medicine.

[32]  M. Makuuchi,et al.  Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version , 2011, Digestive Diseases.

[33]  R. Merion,et al.  Racial and ethnic disparities in access to liver transplantation , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  Jeong Min Lee,et al.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma , 2010, Hepatology international.

[35]  Raymond T Chung,et al.  Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  G. Casazza,et al.  Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.

[37]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[38]  V. Chen,et al.  Screening for Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis: A Cost-Utility Analysis , 2003, American Journal of Gastroenterology.

[39]  Recinda L. Sherman,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival , 2017, Journal of the National Cancer Institute.

[40]  Claude B. Sirlin,et al.  Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid , 2016, Abdominal Radiology.

[41]  Jasmin A. Tiro,et al.  Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. , 2015, The American journal of medicine.

[42]  K. Ge,et al.  Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China , 2007, International Journal of Obesity.

[43]  M. Thun,et al.  Re: annual report to the nation on the status of cancer (1973 through 1998), featuring cancer with recent increasing trends. , 2001, Journal of the National Cancer Institute.

[44]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.